• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

初发性和记忆性 T 细胞在晚期 NSCLC 中的临床预测价值。

Clinical predictive value of naïve and memory T cells in advanced NSCLC.

机构信息

Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China.

National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China.

出版信息

Front Immunol. 2022 Sep 2;13:996348. doi: 10.3389/fimmu.2022.996348. eCollection 2022.

DOI:10.3389/fimmu.2022.996348
PMID:36119064
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9478592/
Abstract

Currently, there is no sensitive prognostic biomarker to screen out benefit patients from the non-benefit population in advanced non-small cell lung cancer patients (aNSCLCs). The 435 aNSCLCs and 278 normal controls (NCs) were recruited. The percentages and absolute counts (AC) of circulating naïve and memory T lymphocytes of CD4 and CD8 T cells (Tn/Tm) were measured by flow cytometry. The percentage of CD4 naïve T (Tn), CD8 Tn, CD8 T memory stem cell (Tscm), and CD8 terminal effector T cell decreased obviously. Still, all AC of Tn/Tm of aNSCLCs was significantly lower compared to NCs. Higher AC and percentage of CD4 Tn, CD8 Tn, and CD4 Tscm showed markedly longer median PFS in aNSCLCs. Statistics demonstrated the AC of CD4 Tn (≥ 3.7 cells/μL) was an independent protective factor for PFS. The analysis of the prognosis of immunotherapy showed the higher AC and percentage of CD4 Tn and CD4 Tscm and higher AC of CD8 Tscm had significantly longer median PFS and the AC of CD4 Tn (≥ 5.5 cells/μL) was an independent protective factor for PFS. Moreover, higher AC and percentages of Tn/Tm suggested higher disease control rate and lower progressive disease rate. The AC of Tn/Tm showed more regular patterns of impairment and was more relative with the disease progression than percentages in aNSCLCs. AC had a better predictive value than percentages in Tn/Tm for PFS. Notably, the AC of CD4 Tn was a potential prognostic biomarker for the PFS and efficacy of immunotherapy.

摘要

目前，尚无敏感的预后生物标志物可从晚期非小细胞肺癌（aNSCLC）患者的无获益人群中筛选出获益患者。招募了 435 名 aNSCLC 患者和 278 名正常对照者（NCs）。通过流式细胞术测量了 CD4 和 CD8 T 细胞（Tn/Tm）循环幼稚和记忆 T 淋巴细胞的百分比和绝对计数（AC）。CD4 幼稚 T（Tn）、CD8 Tn、CD8 记忆干细胞（Tscm）和 CD8 终末效应 T 细胞的百分比明显降低。尽管如此，与 NCs 相比，aNSCLC 的所有 Tn/Tm 的 AC 均明显降低。较高的 AC 和百分比的 CD4 Tn、CD8 Tn 和 CD4 Tscm 在 aNSCLC 中显示出明显更长的中位无进展生存期（PFS）。统计学表明，CD4 Tn 的 AC（≥3.7 个细胞/μL）是 PFS 的独立保护因素。免疫疗法预后分析表明，较高的 AC 和百分比的 CD4 Tn 和 CD4 Tscm 以及较高的 CD8 Tscm 的 AC 具有明显更长的中位 PFS，而 CD4 Tn（≥5.5 个细胞/μL）的 AC 是 PFS 的独立保护因素。此外，较高的 AC 和 Tn/Tm 的百分比提示更高的疾病控制率和更低的疾病进展率。与百分比相比，Tn/Tm 的 AC 显示出更规律的损伤模式，与疾病进展更相关。AC 对 PFS 的预测价值优于 Tn/Tm 的百分比。值得注意的是，CD4 Tn 的 AC 是 PFS 和免疫疗法疗效的潜在预后生物标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f025/9478592/6fee49a63d12/fimmu-13-996348-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f025/9478592/69bf63f3340c/fimmu-13-996348-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f025/9478592/f1b4dac00750/fimmu-13-996348-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f025/9478592/ef732fbe9088/fimmu-13-996348-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f025/9478592/9be0e99bfac3/fimmu-13-996348-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f025/9478592/b3662dbb2fbc/fimmu-13-996348-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f025/9478592/26bea0ae76f9/fimmu-13-996348-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f025/9478592/9f60ef215618/fimmu-13-996348-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f025/9478592/6fee49a63d12/fimmu-13-996348-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f025/9478592/69bf63f3340c/fimmu-13-996348-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f025/9478592/f1b4dac00750/fimmu-13-996348-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f025/9478592/ef732fbe9088/fimmu-13-996348-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f025/9478592/9be0e99bfac3/fimmu-13-996348-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f025/9478592/b3662dbb2fbc/fimmu-13-996348-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f025/9478592/26bea0ae76f9/fimmu-13-996348-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f025/9478592/9f60ef215618/fimmu-13-996348-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f025/9478592/6fee49a63d12/fimmu-13-996348-g008.jpg

相似文献

1
Clinical predictive value of naïve and memory T cells in advanced NSCLC.初发性和记忆性 T 细胞在晚期 NSCLC 中的临床预测价值。
Front Immunol. 2022 Sep 2;13:996348. doi: 10.3389/fimmu.2022.996348. eCollection 2022.
2
Peripheral CD4 T cell signatures in predicting the responses to anti-PD-1/PD-L1 monotherapy for Chinese advanced non-small cell lung cancer.外周血CD4 T细胞特征在预测中国晚期非小细胞肺癌抗PD-1/PD-L1单药治疗反应中的作用
Sci China Life Sci. 2021 Oct;64(10):1590-1601. doi: 10.1007/s11427-020-1861-5. Epub 2021 Jan 29.
3
Circulating memory PD-1CD8 T cells and PD-1CD8T/PD-1CD4T cell ratio predict response and outcome to immunotherapy in advanced gastric cancer patients.循环记忆性PD-1 CD8 T细胞和PD-1 CD8 T/PD-1 CD4 T细胞比值可预测晚期胃癌患者免疫治疗的反应和预后。
Cancer Cell Int. 2023 Nov 16;23(1):274. doi: 10.1186/s12935-023-03137-9.
4
Predictive response and outcome of peripheral CD4 T cell subpopulations to combined immunotherapy and chemotherapy in advanced gastric cancer patients.晚期胃癌患者外周血CD4 T细胞亚群对联合免疫治疗和化疗的预测反应及结果
Int Immunopharmacol. 2024 Mar 10;129:111663. doi: 10.1016/j.intimp.2024.111663. Epub 2024 Feb 15.
5
Association of lymphocyte subsets with efficacy and prognosis of immune checkpoint inhibitor therapy in advanced non-small cell lung carcinoma: a retrospective study.淋巴细胞亚群与晚期非小细胞肺癌免疫检查点抑制剂治疗疗效和预后的相关性：一项回顾性研究。
BMC Pulm Med. 2022 Apr 28;22(1):166. doi: 10.1186/s12890-022-01951-x.
6
CD8PD-1 to CD4PD-1 ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockers.CD8PD-1 与 CD4PD-1 比值（PERLS）与接受 PD-(L)1 抑制剂治疗的晚期 NSCLC 患者的预后相关。
J Immunother Cancer. 2022 Feb;10(2). doi: 10.1136/jitc-2021-004012.
7
The Characteristics of Naive-like T Cells in Tumor-infiltrating Lymphocytes From Human Lung Cancer.人肺癌肿瘤浸润淋巴细胞中类初始T细胞的特征
J Immunother. 2017 Jan;40(1):1-10. doi: 10.1097/CJI.0000000000000147.
8
Circulating activated immune cells as a potential blood biomarkers of non-small cell lung cancer occurrence and progression.循环激活免疫细胞作为非小细胞肺癌发生和进展的潜在血液生物标志物。
BMC Pulm Med. 2021 Sep 6;21(1):282. doi: 10.1186/s12890-021-01636-x.
9
The Distribution of Human Stem Cell-like Memory T Cell in Lung Cancer.人干细胞样记忆T细胞在肺癌中的分布
J Immunother. 2016 Jul-Aug;39(6):233-40. doi: 10.1097/CJI.0000000000000128.
10
Prognostic value of CD4+ T lymphopenia in non-small cell lung Cancer.CD4+ T 淋巴细胞减少对非小细胞肺癌的预后价值。
BMC Cancer. 2022 May 11;22(1):529. doi: 10.1186/s12885-022-09628-8.

引用本文的文献

1
Decoupled dynamics of absolute and relative lymphocyte counts and age-polarized CD4/CD8 ratio in infants versus older adults.婴儿与老年人中绝对和相对淋巴细胞计数的解耦动力学以及年龄极化的CD4/CD8比值
Front Immunol. 2025 Jul 24;16:1599515. doi: 10.3389/fimmu.2025.1599515. eCollection 2025.
2
Predictive role of peripheral blood indicators in the prognosis of patients with cutaneous squamous cell carcinoma treated with immune checkpoint inhibitors.外周血指标对接受免疫检查点抑制剂治疗的皮肤鳞状细胞癌患者预后的预测作用
Am J Cancer Res. 2025 Apr 15;15(4):1705-1718. doi: 10.62347/KZOQ9722. eCollection 2025.
3
Peripheral T lymphocyte immune characteristics dictate response to transarterial chemoembolization in unresectable hepatocellular carcinoma.

本文引用的文献

1
Association of lymphocyte subsets with efficacy and prognosis of immune checkpoint inhibitor therapy in advanced non-small cell lung carcinoma: a retrospective study.淋巴细胞亚群与晚期非小细胞肺癌免疫检查点抑制剂治疗疗效和预后的相关性：一项回顾性研究。
BMC Pulm Med. 2022 Apr 28;22(1):166. doi: 10.1186/s12890-022-01951-x.
2
CD8PD-1 to CD4PD-1 ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockers.CD8PD-1 与 CD4PD-1 比值（PERLS）与接受 PD-(L)1 抑制剂治疗的晚期 NSCLC 患者的预后相关。
J Immunother Cancer. 2022 Feb;10(2). doi: 10.1136/jitc-2021-004012.
3
Association of Baseline and Pharmacodynamic Biomarkers With Outcomes in Patients Treated With the PD-1 Inhibitor Budigalimab.
外周血T淋巴细胞免疫特征决定不可切除肝细胞癌经动脉化疗栓塞术的疗效。
Therap Adv Gastroenterol. 2025 May 5;18:17562848251333295. doi: 10.1177/17562848251333295. eCollection 2025.
4
CD8+ T Cell Subsets as Biomarkers for Predicting Checkpoint Therapy Outcomes in Cancer Immunotherapy.CD8+ T细胞亚群作为预测癌症免疫治疗中检查点治疗结果的生物标志物
Biomedicines. 2025 Apr 9;13(4):930. doi: 10.3390/biomedicines13040930.
5
Low levels of CD3 + and CD8 + T cells in peripheral blood can predict poor efficacy of first-line chemotherapy in patients with angioimmunoblastic T cell lymphoma.外周血中CD3 +和CD8 + T细胞水平较低可预测血管免疫母细胞性T细胞淋巴瘤患者一线化疗疗效不佳。
Ann Hematol. 2025 Mar;104(3):1705-1712. doi: 10.1007/s00277-025-06314-0. Epub 2025 Mar 26.
6
Early changes of peripheral circulating immune subsets induced by PD-1 inhibitors in patients with advanced malignant melanoma and non-small cell lung cancer.程序性死亡受体1（PD-1）抑制剂对晚期恶性黑色素瘤和非小细胞肺癌患者外周循环免疫亚群的早期影响
BMC Cancer. 2024 Dec 30;24(1):1590. doi: 10.1186/s12885-024-13351-x.
7
PI3K/AKT/mTOR and PD‑1/CTLA‑4/CD28 pathways as key targets of cancer immunotherapy (Review).PI3K/AKT/mTOR和PD-1/CTLA-4/CD28信号通路作为癌症免疫治疗的关键靶点（综述）
Oncol Lett. 2024 Sep 26;28(6):567. doi: 10.3892/ol.2024.14700. eCollection 2024 Dec.
8
Diversity of Memory CD8 T Cells in Tumor-Draining Lymph Nodes from Patients with Bladder Cancer.膀胱癌患者肿瘤引流淋巴结中记忆性CD8 T细胞的多样性
Int J Mol Cell Med. 2024;13(2):147-159. doi: 10.22088/IJMCM.BUMS.13.2.147.
9
The profile and prognostic significance of bone marrow T-cell differentiation subsets in adult AML at diagnosis.成人 AML 诊断时骨髓 T 细胞分化亚群的特征和预后意义。
Front Immunol. 2024 Jul 19;15:1418792. doi: 10.3389/fimmu.2024.1418792. eCollection 2024.
10
Memory inflation: Beyond the acute phase of viral infection.记忆膨胀：超越病毒感染的急性期
Cell Prolif. 2024 Dec;57(12):e13705. doi: 10.1111/cpr.13705. Epub 2024 Jul 11.
接受 PD-1 抑制剂 Budigalimab 治疗的患者中，基线和药效学生物标志物与结局的关联。
J Immunother. 2022 Apr 1;45(3):167-179. doi: 10.1097/CJI.0000000000000408.
4
Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial.度伐利尤单抗联合替西木单抗单药或联合低剂量或亚分次放疗治疗既往 PD-(L)1 治疗耐药的转移性非小细胞肺癌：一项开放标签、多中心、随机、2 期临床试验。
Lancet Oncol. 2022 Feb;23(2):279-291. doi: 10.1016/S1470-2045(21)00658-6. Epub 2022 Jan 13.
5
Reference range of naïve T and T memory lymphocyte subsets in peripheral blood of healthy adult.健康成年人外周血初始 T 和 T 记忆淋巴细胞亚群的参考范围。
Clin Exp Immunol. 2022 Apr 4;207(2):208-217. doi: 10.1093/cei/uxab038.
6
CD4 Memory Stem T Cell in Peripheral Blood: A Promising Immune Index for Early Screening and Auxiliary Diagnosis of Colorectal Cancer.外周血CD4记忆性干细胞T细胞：一种用于结直肠癌早期筛查和辅助诊断的有前景的免疫指标。
Front Oncol. 2021 Jul 13;11:701738. doi: 10.3389/fonc.2021.701738. eCollection 2021.
7
Progressive immune dysfunction with advancing disease stage in renal cell carcinoma.在肾癌的疾病进展阶段，免疫功能逐渐受损。
Cancer Cell. 2021 May 10;39(5):632-648.e8. doi: 10.1016/j.ccell.2021.02.013. Epub 2021 Mar 11.
8
NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021.NCCN 指南解读：非小细胞肺癌，第 2.2021 版。
J Natl Compr Canc Netw. 2021 Mar 2;19(3):254-266. doi: 10.6004/jnccn.2021.0013.
9
PAF remodels the DREAM complex to bypass cell quiescence and promote lung tumorigenesis.PAF 重塑 DREAM 复合物以绕过细胞静止并促进肺肿瘤发生。
Mol Cell. 2021 Apr 15;81(8):1698-1714.e6. doi: 10.1016/j.molcel.2021.02.001. Epub 2021 Feb 23.
10
Peripheral CD4 T cell signatures in predicting the responses to anti-PD-1/PD-L1 monotherapy for Chinese advanced non-small cell lung cancer.外周血CD4 T细胞特征在预测中国晚期非小细胞肺癌抗PD-1/PD-L1单药治疗反应中的作用
Sci China Life Sci. 2021 Oct;64(10):1590-1601. doi: 10.1007/s11427-020-1861-5. Epub 2021 Jan 29.